Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event

BACKGROUND: Imatinib mesylate has been the standard therapeutic treatment for chronic myeloid leukemia, advanced and metastatic gastrointestinal stromal tumor (GIST). It is well tolerated with mild adverse effects. Gynecomastia development during the course of treatment has been rarely reported. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, HeLi, Liao, GuoQing, Yan, ZhongShu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217900/
https://www.ncbi.nlm.nih.gov/pubmed/22047550
http://dx.doi.org/10.1186/1471-230X-11-116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217900/
https://www.ncbi.nlm.nih.gov/pubmed/22047550
http://dx.doi.org/10.1186/1471-230X-11-116

Ejemplares similares